Abstract
The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.
© 2015 American Society for Clinical Pharmacology and Therapeutics.
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Biomarkers, Tumor / genetics
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / enzymology
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Drug Discovery / methods*
-
Early Detection of Cancer
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
ErbB Receptors / metabolism
-
Genomics*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Molecular Targeted Therapy*
-
Mutation
-
Precision Medicine
-
Predictive Value of Tests
-
Protein Kinase Inhibitors / therapeutic use
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
-
Receptor Protein-Tyrosine Kinases / genetics
-
Receptor Protein-Tyrosine Kinases / metabolism
-
Signal Transduction / drug effects
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Protein Kinase Inhibitors
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
EGFR protein, human
-
ErbB Receptors
-
Receptor Protein-Tyrosine Kinases